Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Research analysts at Oppenheimer Holdings boosted their FY2017 earnings per share (EPS) estimates for Agios Pharmaceuticals in a report issued on Wednesday. Oppenheimer Holdings analyst L. Cann now anticipates that the biopharmaceutical company will post earnings per share of ($6.63) for the year, up from their previous estimate of ($7.39). Oppenheimer Holdings has a “Outperform” rating and a $83.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Agios Pharmaceuticals’ Q4 2017 earnings at ($1.69) EPS, Q1 2018 earnings at ($2.06) EPS, Q2 2018 earnings at ($2.21) EPS, Q3 2018 earnings at ($2.37) EPS, Q4 2018 earnings at ($0.58) EPS, FY2018 earnings at ($7.22) EPS, FY2019 earnings at ($1.42) EPS, FY2020 earnings at $3.07 EPS and FY2021 earnings at $5.68 EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same period in the prior year, the business earned ($1.63) earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/08/oppenheimer-holdings-brokers-lift-earnings-estimates-for-agios-pharmaceuticals-inc-agio.html.

Several other brokerages also recently commented on AGIO. BidaskClub downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada initiated coverage on shares of Agios Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $78.00 target price for the company. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Finally, Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Agios Pharmaceuticals has an average rating of “Buy” and an average target price of $75.70.

Agios Pharmaceuticals (NASDAQ:AGIO) opened at $67.25 on Monday. Agios Pharmaceuticals has a twelve month low of $39.24 and a twelve month high of $72.73.

In related news, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total transaction of $134,532.74. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $56.85, for a total transaction of $227,400.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 178,908 shares of company stock valued at $12,147,719. 10.55% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. Macquarie Group Ltd. acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth approximately $245,000. Ameriprise Financial Inc. boosted its position in Agios Pharmaceuticals by 15.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 57,504 shares of the biopharmaceutical company’s stock worth $3,838,000 after buying an additional 7,510 shares during the period. Hood River Capital Management LLC boosted its position in Agios Pharmaceuticals by 2.1% during the 3rd quarter. Hood River Capital Management LLC now owns 121,390 shares of the biopharmaceutical company’s stock worth $8,103,000 after buying an additional 2,546 shares during the period. Bank of New York Mellon Corp boosted its position in Agios Pharmaceuticals by 3.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 176,405 shares of the biopharmaceutical company’s stock worth $11,775,000 after buying an additional 6,632 shares during the period. Finally, Teacher Retirement System of Texas acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth approximately $225,000. 93.51% of the stock is currently owned by institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.